Who are P2Y12 Receptor Antagonist's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Clopidogrel 75, Dual antiplatelet agent duration, Aspirin + Clopidogrel + Rivaroxaban, Aspirin or thienopyridine, Ticagrelor followed with Methoxyflurane, Double antiplatelet therapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/p2y12-receptor-antagonist.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

P2Y12 Receptor Antagonist — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

P2Y12 Receptor Antagonist (P2Y12 Receptor Antagonist) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: P2Y12 receptor antagonist. Area: Cardiovascular.

marketed P2Y12 receptor antagonist P2Y12 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

P2Y12 Receptor Antagonist (P2Y12 Receptor Antagonist) — Fu Wai Hospital, Beijing, China. Blocks the P2Y12 adenosine diphosphate receptor on platelets to inhibit platelet aggregation and reduce thrombotic events.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
P2Y12 Receptor Antagonist TARGET	P2Y12 Receptor Antagonist	Fu Wai Hospital, Beijing, China	marketed	P2Y12 receptor antagonist	P2Y12 receptor
Clopidogrel 75	Clopidogrel 75	US Department of Veterans Affairs	marketed	P2Y12 receptor antagonist / Thienopyridine antiplatelet agent	P2Y12 receptor
Dual antiplatelet agent duration	Dual antiplatelet agent duration	Seoul National University Hospital	marketed	Antiplatelet agent combination	Cyclooxygenase (COX) and P2Y12 receptor
Aspirin + Clopidogrel + Rivaroxaban	Aspirin + Clopidogrel + Rivaroxaban	China National Center for Cardiovascular Diseases	marketed	Antiplatelet agent + Anticoagulant combination	Platelet cyclooxygenase, P2Y12 receptor, Factor Xa
Aspirin or thienopyridine	Aspirin or thienopyridine	Associations for Establishment of Evidence in Interventions	marketed	Antiplatelet agents	COX-1 (aspirin); P2Y12 receptor (thienopyridines)
Ticagrelor followed with Methoxyflurane	Ticagrelor followed with Methoxyflurane	Collegium Medicum w Bydgoszczy	marketed	Antiplatelet agent combined with volatile analgesic	P2Y12 receptor (ticagrelor); NMDA receptor and other targets (methoxyflurane)
Double antiplatelet therapy	Double antiplatelet therapy	University Hospital, Bordeaux	marketed	Antiplatelet combination therapy	Cyclooxygenase (COX) and P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (P2Y12 receptor antagonist class)

First Affiliated Hospital of Harbin Medical University · 4 drugs in this class
Fu Wai Hospital, Beijing, China · 1 drug in this class
Ping-Yen Liu · 1 drug in this class
Samsung Medical Center · 1 drug in this class
St. Antonius Hospital · 1 drug in this class
University of Florida · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). P2Y12 Receptor Antagonist — Competitive Intelligence Brief. https://druglandscape.com/ci/p2y12-receptor-antagonist. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab